Innovent's Trispecific Antibody IBI3003 Shows Strong Phase 1 Results in Relapsed Multiple Myeloma
Event summary
- Innovent Biologics announced updated Phase 1 clinical data for IBI3003, a trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM).
- The recommended Phase 2 dose (RP2D) of IBI3003 was determined to be 360 μg/kg, demonstrating an overall response rate (ORR) of 84.6% at this dose.
- The Phase 1 study enrolled 102 patients in China and Australia, with a median follow-up duration of 6.65 months as of June 30, 2026.
- IBI3003 showed a manageable safety profile, with hematologic toxicities being the most common Grade ≥3 treatment-related adverse events.
- Innovent is conducting Phase 1/2 clinical trials of IBI3003 in China, Australia, and the United States, and has advanced the Phase 3 TriadicMM-1 study in China.
The big picture
Innovent's IBI3003 represents a significant advancement in the treatment of relapsed or refractory multiple myeloma, addressing the unmet clinical need for therapies that can overcome treatment resistance caused by antigen escape. The trispecific antibody's dual-targeting design against BCMA and GPRC5D positions it as a potential game-changer in the oncology space, particularly for heavily pretreated and high-risk patients. The ongoing Phase 3 TriadicMM-1 study will be critical in determining the long-term clinical value of IBI3003.
What we're watching
- Clinical Efficacy
- How the 84.6% overall response rate at the recommended Phase 2 dose will position IBI3003 against existing therapies in the relapsed or refractory multiple myeloma market.
- Regulatory Pathway
- The pace at which Innovent can advance IBI3003 through Phase 3 trials and potential regulatory approval, given the promising Phase 1 data.
- Commercial Strategy
- Whether Innovent can leverage its strategic partnerships to accelerate the global commercialization of IBI3003, particularly in key markets like the United States and Europe.